Skip to main content

Table 2 Comparing risks for dementia between patients with PA and their EH matches after treatment initiation

From: Risk of dementia in primary aldosteronism compared with essential hypertension: a nationwide cohort study

 

Number of events

Person-years

Cumulative incidence/1,000 person-years

Univariable Cox regression

Multivariable Cox regressiona

Model 1

Model 2

Model 3

HR (95%CI)

p-value

HR (95%CI)

p-value

HR (95%CI)

p-value

HR (95%CI)

p-value

All-cause dementia

 EH (reference)

522

88,156

5.92

1.00

 

1.00

 

1.00

 

1.00

 

 PA (Total)

156

20,953

7.45

1.26 (1.05–1.51)

0.011

1.26 (1.06–1.52)

0.011

0.90 (0.74–1.10)

0.317

1.20 (0.95–1.51)

0.134

 PA (ADX)

18

8317

2.16

0.35 (0.22–0.57)

 < 0.001

0.35 (0.22–0.57)

 < .0001

0.28 (0.17–0.46)

 < 0.001

0.69 (0.41–1.15)

0.157

 PA (MRA)

138

12,637

10.92

1.88 (1.56–2.27)

 < 0.001

1.87 (1.55–2.26)

 < .0001

1.30 (1.06–1.61)

0.013

1.31 (1.03–1.67)

0.027

Alzheimer disease

 EH (reference)

475

88,257

5.38

1.00

 

1.00

 

1.00

 

1.00

 

 PA (Total)

140

20,979

6.67

1.24 (1.03–1.50)

0.027

1.24 (1.02–1.50)

0.029

0.87 (0.71–1.08)

0.209

1.17 (0.91–1.49)

0.220

 PA (ADX)

16

8322

1.92

0.34 (0.20–0.56)

 < 0.001

0.34 (0.20–0.56)

 < .0001

0.27 (0.16–0.45)

 < 0.001

0.68 (0.40–1.18)

0.172

 PA (MRA)

124

12,657

9.80

1.85 (1.51–2.26)

 < 0.001

1.84 (1.51–2.25)

 < .0001

1.26 (1.01–1.58)

0.039

1.27 (0.99–1.63)

0.062

Vascular dementia

 EH (reference)

169

89,192

1.89

1.00

 

1.00

 

1.00

 

1.00

 

 PA (Total)

65

21,207

3.06

1.64 (1.23–2.18)

0.001

1.64 (1.23–2.19)

0.001

1.16 (0.85–1.60)

0.352

1.59 (1.07–2.36)

0.020

 PA (ADX)

12

8338

1.44

0.76 (0.42–1.37)

0.358

0.78 (0.43–1.40)

0.404

0.64 (0.35–1.16)

0.141

1.45 (0.75–2.81)

0.265

 PA (MRA)

53

12,869

4.12

2.21 (1.62–3.02)

 < 0.001

2.19 (1.61–2.99)

 < 0.001

1.48 (1.05–2.10)

0.026

1.62 (1.08–2.45)

0.020

  1. Abbreviations: ADX adrenalectomy, CI confidence interval, EH essential hypertension, HR hazard ratio, MRA mineralocorticoid receptor antagonist, PA primary aldosteronism
  2. aModel 1: age, sex, and income; Model 2: model 1 + baseline comorbidities (diabetes mellitus, dyslipidemia, chronic kidney disease, atrial fibrillation, non-fatal stroke, and non-fatal myocardial infarction); Model 3: model 2 + prescribed medications (angiotensin II receptor antagonists/angiotensin-converting-enzyme inhibitor (ARB/ACE inhibitor), β-blocker, calcium channel blocker (CCB), diuretics, statins, and antithrombotics)
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193